Tenderwize
Retour à la recherche

Open House Pharmaceutical Rebate Contracts Timolol and Tafluprost (ATC S01ED70)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 03, 2027 · 369 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Timolol und Tafluprost, ATC S01ED70

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

The open-house contract can be automatically terminated if a conventional rebate contract for Timolol/Tafluprost comes...

Incorrect submission format (e.g., scanning without qualified signature, missing original copies) can delay contract st...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Non-exclusive discount agreements (Rabattverträge) for pharmaceutical products with active substances Timolol and Tafluprost (ATC S01ED70) under § 130a Abs. 8 SGB V.
Afficher le résumé complet

This is an open-house model for non-exclusive pharmaceutical rebate agreements (Rabattverträge) for the active substances Timolol and Tafluprost (ATC S01ED70) with AOK Bayern. Unlike a traditional tender, all eligible pharmaceutical enterprises can enter into identical, non-negotiable contracts during the window until 2027-09-03. The contracts run from 2025-11-01 to 2027-10-31. No award criteria apply; participation is open to all qualified pharmaceutical companies. The estimated contract value is not disclosed. The notice explicitly states this is not a procurement procedure under EU procurement law but an open-house model.

Risques

The open-house contract can be automatically terminated if a conventional rebate contract for Timolol/Tafluprost comes...

Incorrect submission format (e.g., scanning without qualified signature, missing original copies) can delay contract st...

Exigences clés

Technical

  • Only pharmaceutical enterprises (pharmazeutische Unternehmen) may participate.

Certifications

  • Documents must be submitted in German (or with certified German translation).

Administrative

  • Submission either in paper form (2 original copies signed by hand) or electronically with qualified electronic signature via the DTVP communication area.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open House Pharmaceutical Rebate Contracts Timolol and Tafluprost (ATC S01ED70)

Non-exclusive discount agreements for pharmaceutical products containing Timolol and Tafluprost (ATC S01ED70). Contract conclusion possible from 2025-11-01 to 2027-09-03. All contracts end on 2027-10-31. Subject to automatic termination if a nationwide or regional rebate contract (open procedure) for the same active substance takes effect.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Oct 2025 - Oct 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Sep 03, 2027

Détails de la procédure

Date de publication
14 Sep 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
599161-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30